San Diego, CA (PRWEB) March 26, 2015
Immune recognition and elimination of pathogenic organisms as well as cancerous cells requires a well-orchestrated series of steps that includes a combination of co-stimulatory and co-inhibitory pathways. A large number of immune co-regulatory pathways are initiated by receptor/ligand pairs expressed on the surface of cells of both the innate and adaptive immune systems. These receptor/ligand pairs are easily accessible and are often the targets of immunotherapies, treatments designed to modulate the immune system in a way that helps fight disease. Depending on the particular disease, immunotherapies can either activate or inhibit the immune system, with cancer and autoimmune diseases being respective examples.
“We are in the midst of a very exciting time in medicine right now, with many recent success stories in the area of cancer immunotherapy,” said BPS President and CEO, Henry Zhu, PhD. “It is our goal to provide scientists with all of the resources they need to accelerate the process of cancer immunotherapy drug discovery and development.” In line with this, BPS has recently expanded its already large portfolio of unique biotin-labeled immunotherapy proteins. Due to the exceptionally strong interaction between biotin and either avidin or streptavidin, biotin-labeled proteins are easily detected and can be used in ELISA-based receptor/ligand binding assay or immobilized on beads or streptavidin-coated surfaces for cellular assays, making them very versatile. “We think of these biotin-labeled proteins as another tool in the drug discovery scientist’s toolbox,” said Dr. Zhu.
As an example of the utility of these proteins, BPS has developed several inhibitor screening assay kits that take advantage of these biotin-labeled receptors for the detection of receptor/ligand interaction. BPS’ portfolio of immunotherapy proteins includes the biotin-labeled receptors PD-1, PD-L1, PD-L2, Lag-3, Sirp-α, B7-1, and more. In addition to receptors, BPS also offers biotin-labeled neutralizing antibodies to several immunotherapy targets, including PD-1, PD-L1, and CTLA4. All of BPS’ biotin-labeled proteins and antibodies come in non-biotinylated versions as well and BPS will continue to add to their immunotherapy portfolio.
To learn more about BPS Bioscience’s immunotherapy products, visit our website at http://bpsbioscience.com/immunotherapy.
About BPS Bioscience
BPS Bioscience, Inc. is a leading manufacturer of recombinant proteins and assay kits for life science and drug discovery research. In addition to Immunotherapy, BPS supplies products and services for Acetyltransferases, Bromodomains, HDACs, Histone Demethylases, Methyltransferases, Kinases, Phosphatases, Phosphodiesterases, Poly ADP Ribose Polymerases (PARPs), and Protease research. BPS also provides custom protein expression, biochemical and cell-based assays, and compound screening and profiling services. Headquartered in San Diego, California, BPS has provided products and services to pharmaceutical companies and academic institutes in over 45 countries worldwide. By being at the forefront of technology development, BPS provides innovative, high quality life science products and services in a timely manner to help our customers accelerate drug discovery and development for the treatment of human diseases.
Visit BPS’s website for more information: http://www.bpsbioscience.com.